Literature DB >> 14519102

The growth hormone receptor interacts with its sheddase, the tumour necrosis factor-alpha-converting enzyme (TACE).

Julia A Schantl1, Marcel Roza, Peter Van Kerkhof, Ger J Strous.   

Abstract

Proteolysis of the GHR (growth hormone receptor) occurs at the cell surface and results in the release of its extracellular domain, the GHBP (growth hormone-binding protein). TACE (tumour necrosis factor-alpha-converting enzyme) has been identified as a putative protease responsible for GHR cleavage. However, GHR-TACE interaction has not been observed until now. Here, we identified TACE in Chinese hamster cells and confirmed processing and cell-surface expression. Interaction between GHR and TACE was only observed after growth hormone binding. As the growth hormone-GHR(2) complex is a poor substrate for TACE, we conclude that the GHR-TACE interaction precedes proteolysis, and is transient. Furthermore, we demonstrate that TACE is present in endosomes, where it partly co-localizes with endocytosed growth hormone ligand.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14519102      PMCID: PMC1223864          DOI: 10.1042/BJ20031321

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  A method to increase the number of growth hormone receptors at the surface of cells.

Authors:  Peter van Kerkhof; Erica Vallon; Ger J Strous
Journal:  Mol Cell Endocrinol       Date:  2003-03-28       Impact factor: 4.102

2.  Monkey growth hormone (GH) receptor gene expression. Evidence for two mechanisms for the generation of the GH binding protein.

Authors:  J F Martini; A Pezet; C Y Guezennec; M Edery; M C Postel-Vinay; P A Kelly
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

3.  Mouse serum growth hormone (GH) binding protein has GH receptor extracellular and substituted transmembrane domains.

Authors:  W C Smith; J Kuniyoshi; F Talamantes
Journal:  Mol Endocrinol       Date:  1989-06

4.  A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein.

Authors:  R J Ross; N Esposito; X Y Shen; S Von Laue; S L Chew; P R Dobson; M C Postel-Vinay; J Finidori
Journal:  Mol Endocrinol       Date:  1997-03

5.  Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme.

Authors:  J R Doedens; R A Black
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

6.  Phorbol ester- and growth factor-induced growth hormone (GH) receptor proteolysis and GH-binding protein shedding: relationship to GH receptor down-regulation.

Authors:  R Guan; Y Zhang; J Jiang; C A Baumann; R A Black; G Baumann; S J Frank
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

7.  Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE).

Authors:  J Schlöndorff; J D Becherer; C P Blobel
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

8.  Blockade of growth hormone receptor shedding by a metalloprotease inhibitor.

Authors:  J Alele; J Jiang; J F Goldsmith; X Yang; H G Maheshwari; R A Black; G Baumann; S J Frank
Journal:  Endocrinology       Date:  1998-04       Impact factor: 4.736

9.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.

Authors:  K Maskos; C Fernandez-Catalan; R Huber; G P Bourenkov; H Bartunik; G A Ellestad; P Reddy; M F Wolfson; C T Rauch; B J Castner; R Davis; H R Clarke; M Petersen; J N Fitzner; D P Cerretti; C J March; R J Paxton; R A Black; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor.

Authors:  W R Baumbach; D L Horner; J S Logan
Journal:  Genes Dev       Date:  1989-08       Impact factor: 11.361

View more
  2 in total

Review 1.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

Review 2.  The ADAM metalloproteinases.

Authors:  Dylan R Edwards; Madeleine M Handsley; Caroline J Pennington
Journal:  Mol Aspects Med       Date:  2008-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.